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Abstract
Objectives: To demonstrate the efficacy of laser photobiomodulation (PBM) compared to that of
placebo on severe oral mucositis (OM) in pediatric oncology patients. The primary objective was
Abbreviations: AIEOP, Italian Pediatric HematologyOncology Association; CT, chemotherapy;MASCC/ISOO,Multinational Association of Supportive Care in Cancer/International Association
of Oral Oncology; OM, oral mucositis; PBM, photobiomodulation;WHO,World Health Organization
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the reduction of OM grade (World Health Organization [WHO] scale) 7 days after starting PBM.
Secondary objectiveswere reduction of pain, analgesic consumption, and incidence of side effects.
Methods:One hundred and one children with WHO grade > 2 chemotherapy-induced OMwere
enrolled in eight Italian hospitals. Patients were randomized to either PBMor sham treatment for
four consecutive days (days+1 to+4). On days+4,+7, and+11, OMgrade, pain (following a 0–10
numeric pain rating scale, NRS) and need for analgesics were evaluated by an operator blinded to
treatment.
Results: Fifty-one patients were allocated to the PBM group, and 50 were allocated to the sham
group. In total, 93.7% of PBM patients and 72% of sham patients had OM grade < 3WHO on day
+7 (P = 0.01). A significant reduction of pain was registered on day +7 in the PBM versus sham
group (NRS 1 [0–3] vs. 2.5 [1–5], P < 0.006). Reduced use of analgesics was reported in the PBM
group, although it was not statistically significant. No significant adverse events attributable to
treatment were recorded.
Conclusions: PBM is a safe, feasible, and effective treatment for children affected by
chemotherapy-inducedOM, as it accelerates mucosal recovery and reduces pain.
K EYWORDS
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1 INTRODUCTION
Oncology patients undergoing cancer treatment are prone to a
series of toxicities, of which oral mucositis (OM) is one of the most
frequent and debilitating. OM can occur after standard and high-
dose chemotherapy1 (CT) and is commonly encountered in patients
receiving hematopoietic stem cell transplantation.2 Children and
adolescents are even more susceptible to OM due to the rapidity
of cellular mitosis and to specific intensive CT regimens for pedi-
atric cancer,3 with incidence varying between 40% and 81% of
cases.4
The general experience in oncology patients is that OM resolves in
conjunctionwith the recoveryof blood counts, but pain and feedingdif-
ficulties due to severe OM frequently lead to hospitalization for pain
control, fluid replacement, and nutritional support.5
At present, no standard treatment of OM is defined, and aggressive
pain management, mucosal coating agents, and local antiseptics are
employed. In recent years, the role of laser therapy, which has recently
been renamed photobiomodulation (PBM),6 has been investigated and
this approach is now a recommended option by Multinational Associ-
ation of Supportive Care in Cancer/International Association of Oral
Oncology (MASCC/ISOO) guidelines for patients receiving high-dose
chemotherapy or transplants.7,8
Opinions regarding the mechanism of action are controversial, but
recent studies have demonstrated a reduction of oxidative stress
and a direct activation of intracellular chromophores following PBM,
thereby triggering an increased proliferation of endothelial cells, ker-
atinocytes, fibroblasts, osteoblasts, and pericytes, with biomodulatory
and analgesic effects.9
One controlled randomized study on a small number of patients has
been published on the use of PBM in children affected byOM,10 which
supported its effectiveness.
We conducted a preliminary investigation of laser therapy in chil-
dren treated in a single institution after CT and, in some cases, total-
body irradiation, where relevant improvement of pain and grade of
mucositis was observed.11 Then, we organized a multicenter random-
ized controlled trial to better define the role of PBM in children
affected by severe OM.
The choice of the employed PBM protocol was derived from pre-
clinical and clinical studies of PBM routinely used for the manage-
ment of anticancer therapy side effects.12–15 According to the liter-
ature, wavelengths between 600 nm and 1,000 nm exert analgesic
and anti-inflammatory effects.16–18 A wavelength of 660 nm is effec-
tive in reducing pain and in healing OM lesions while clinical and pre-
clinical studies have demonstrated that the use of a 970 nm wave-
length combined with high power and energy densities is associated
with better healing and reduced inflammation. In the present study,
the two combined wavelengths were used, aimed at maximizing their
beneficial effects.
2 MATERIALS AND METHODS
This study was a randomized, prospective, multicenter, double-blind
trial investigating the effectiveness of laser therapy (PBM) against
placebo (sham therapy).
The study was supported by the Italian pediatric hemato-oncology
association (AIEOP) supportive care working group and designed
and coordinated by the pediatric hemato-oncology unit of the
Institute for Maternal and Child Health IRCCS Burlo Garofolo,
Trieste, together with the Oral Medicine and Pathology Group (Den-
tal Clinic, University of Trieste). The study involved eight Italian pedi-
atric hemato-oncology centers affiliated with AIEOP (Trieste, Brescia,
Bologna, Cagliari, Padova, Parma, Pavia, Torino) and was performed in
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collaboration with stomatologists of each center. The study protocol
obtained ethical approval by the Independent Bioethics Committee
of the coordinating center on December 3, 2012 (Approval Number:
CE/V 151) and, subsequently, by the ethics committees of each par-
ticipating center. Written informed consent was obtained from each
child's parent or legal surrogate.
The trial was registered at Clinicaltrials.gov (NCT02762019).
2.1 Population
Children of Caucasian origin were included in the study if they met
the following inclusion criteria: age 3–18 years; severe OM of World
Health Organization (WHO) scale19 grade 3 or 4; antiblastic CT in the
previous three weeks; willingness to undergo treatment for 4 consec-
utive days and to return for evaluation 7 and 11 days after enrolment.
Exclusion criteriawere the following: previous treatmentwith PBM
for OM; presence of dysplastic oral lesions; reduction of mouth open-
ing (< 1 cm); localized head and/or neck radiation treatment in the
previous four weeks; use of keratinocyte growth factor; previous
enrollment in the study.
The recruitment of potential participants whomet the inclusion cri-
teria was performed during routine or urgent outpatient evaluation or
among inpatients admitted for any reason.
2.2 Procedures
Randomization was centralized and coordinated by the Clinical
Epidemiology Unit of the coordinating center using a computer-based
method. The randomization list was blocked and stratified by grade
of OM (grade 3 and grade 4) and by center. The allocation conceal-
ment was guaranteed through the use of two sets of closed, opaque
envelopes (one for grade 3 and one for grade 4 OM), consecutively
numbered. Based on the expected recruitment capacity, a certain num-
ber of closed envelopes were sent to each center. As described below,
in each center, the enrolling stomatologist opened the envelope of the
correspondingOMgradewith the lowest number available and started
the treatment indicated.
Operators who performed the treatment were not blinded to the
allocation group. The blindness of enrolled subjectswas guaranteed by
the sham treatment, which was indistinguishable from PBM. Outcome
evaluators were also blinded to the study group.
Theprocedurewasperformedas follows:Onday+1, an initial stom-
atologist evaluated and enrolled the children in the study after collect-
ing clinical and laboratory data, filling out a validated questionnaire
to evaluate OM grade, and opening the envelope of the correspond-
ing OM grade with the lowest number available. The treatment was
then started as indicated in the envelope and continued by the same
stomatologist on day +2, +3 and +4. Starting from day +4, and sub-
sequently, On days +7 and +11, another stomatologist or a trained
onco-hematologic pediatrician, blinded to thepatient's allocation, eval-
uated the outcomes. The questionnaire filled out by the first stomatol-
ogist, containing the information on the group allocation, was stored in
a closed envelope and was not accessible to the outcome evaluators.
Consequently, both enrolled subjects and outcome evaluators were
blinded to the treatment performed.
The severity of OM was evaluated according to the WHO scale,19
graded 0–4, where grade 3 indicates an inability to consume solids and
grade 4 corresponds to complete absence of solid or liquid intake by
mouth.5
Clinical and laboratory data, including blood counts, were collected
on days +1, +4, +7, and +11. Admittance due to isolated OMwas reg-
istered. Buccal swabs for microbiological culture were performed fol-
lowing clinical suspicion for bacterial infection, candidiasis, and herpes
simplex virus infection.
2.3 Treatment
All subjects who met the inclusion/exclusion criteria were randomized
to one of the two study arms.
PBM (experimental arm): Patients were treated with a diode laser
device (class IV, K-Laser Cube series, Eltech K-Laser, Via Castagnole
20/H, Treviso, Italy) over 4 consecutive days, with the following pro-
tocol: 660 and 970 nm-combined wavelengths, 3.2 W peak power,
320mW/cm2 irradiance, 36.8 J/cm2 fluence, and 50% frequency. Laser
application was performed over the entire oral cavity, both in ulcer-
ated and erythematous areas and in areas free of clinical signs. The tis-
sue was irradiated through a rotatory motion over the entire oral cav-
ity (defocused, non-contact modality). The spot size was 1 cm2. Nine
areas in the oral cavity were irradiated maintaining the tip orthog-
onally concerning the tissue: upper lip, lower lip, right side of the
tongue, left side of the tongue, right cheek, left cheek, hard palate,
soft palate, and floor of the mouth. Each of the nine areas received
8 J over 25 sec (total session time: 3 min, 45 sec); the protocol was
performed twice consecutively with 2–3 min intervals between the
two sessions (whole treatment time: 7 min, 30 sec) for 4 consecutive
days.
Sham treatment: Patients received the exact repetition of
the treatment modality but without any laser emission: although
switched off, the laser devices emitted the same sound and showed
the same screen parameters when working in the effective PBM
modality.
Patients, operators, andotherpeoplepresent in the roomduring the
protocol applicationwore protective goggles. Regardless of the alloca-
tion group, patients enrolled in the study received the standard topi-
cal/analgesic treatments for OM used in the enrolling hospital, except
for keratinocyte growth factors (exclusion criteria).
2.4 Outcomes
Theprimary study outcomewas the evaluation ofOMgrade onday+7,
as evaluated with theWHO scale.
The secondary outcomes were OM grade on day +4 and day +11,
reduction of pain evaluated with the validated 0–10 NRS scale (Tom-
linson et al. 2007), reduction in the use of analgesics, and presence of
adverse events.
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2.5 Sample size
The study was designed as a superiority trial. Given the results of the
previously published RCT in children,10 we estimated a priori that the
enrolment of 100 subjects (50 in each group)would provide us a power
of 80% to detect a between-group difference of 30% in the primary
study outcome (i.e., a 70% success rate in the laser treatment group
vs. 40% in the sham treatment group) with a two-sided type I error of
0.05.
2.6 Statistical analysis
Continuous variables are reported as median and interquartile range
(IQR) and categorical variables as proportions and percentages. For
categorical outcomes, between group differences were evaluated
using the chi-squared test or Fisher exact test when appropriate and
for continuous outcomes using the non-parametric Mann–Whitney U
test, as the data were not normally distributed. Analyses were per-
formed with SPSS software (version 21.0) according to the intention-
to-treat principle. Statistically significant differenceswere determined
by a P-value lower than 0.05.
3 RESULTS
3.1 Population
Participants were recruited between September 2013 and October
2015. A total of 102 children with severe OM were admitted at the
eight pediatric hematology oncology units during the study period, of
whom 101 were eligible and were then randomized (in one case, the
parents declined to participate). The two groups were thus 51 in the
laser treatment group and 50 in the sham group. There were no devi-
ations from the random allocation. In the PBM group, one child died
before day +7, one did not return for the scheduled follow up visits on
days +7 and +11 and one did not return for the follow up visit on day
+11. The evaluation of the primary study outcome was performed in
49 and 50 children in the PBM and control group (Fig. 1).
The baseline socio-demographic and clinical characteristics of the
two groups were similar (Table 1): The basic oncological diseases were
equally represented in the two groups, and white blood cells (WBC)
and neutrophil counts were not different in the groups on days+1,+4,
+7, and +11. The buccal swab was performed in 43.8 and 49% of the
patients in the treatmentandcontrol groups,withnon-significantlydif-
ferent low positivity rates for candida (2%) andHSV (2 and 4%) in both
groups. The admittance rate due to isolated OM was not different in
the two groups.
The study results are shown in Table 2.
3.2 Outcomes
3.2.1 Primary outcome
A statistically significant difference in OM grade was observed
between the study groups on day+7.
F IGURE 1 Study flow chart
In the PBMgroup, one subject (2.0%) had severeOMof grade 4 and
two subjects (4.1%) had grade 3 versus eight (16.0%) and six subjects
(12.0%) in the sham group (P< 0.02). Consequently, 6.1% of subjects in
the PBM group versus 28% in sham group had an OM grade of 3 or 4
on day+7 (P< 0.007).
3.2.2 Secondary outcomes
No statistically significant differences in OM grade and self-reported
pain were observed on day +4 while on day +7, a reduction in the
self-reported pain score was statistically significant in the PBM group
(P< 0.007), although the use of analgesics did not vary significantly.
A statistically significant difference between the two groups con-
cerning OM grade and self-reported pain persisted through day +11:
There were no subjects with grade 4 OM and one subject with grade
3 (2.1%) in the PBM group versus five (10%) and five (10%), respec-
tively, in the sham group (P< 0.03). Therefore, 2.1 and 20%of subjects,
respectively, in the PBM and sham group had an OM grade 3 or 4 on
day+11 (P<0.009). Correspondingly, the self-reported pain scorewas
also significantly reduced in the PBM group (P< 0.02).
None of the participants reported clinically evident side effects.
Figure 2 shows the percentage of subjects with severe OM on days 1,
4, 7, and 11 in both groups.
4 DISCUSSION
The primary aim of the study evaluated the reduction of OM at 7 days
from the beginning of PBM. The timing was chosen to allow for com-
parisons with previous findings from the literature10 and as a reason-
able time to consider and evaluate the clinical benefit from treatment,
as OM is expected to heal in 2–3 weeks.17 In both groups, OM tended
to resolve in most patients, but a consistent difference between study
groups was evident on day+7 and persisted until day+11, with a non-
negligible portion of patients still suffering from severeOM in the con-
trol arm. On day +7, only approximately 6% of patients in the PBM
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TABLE 1 Baseline socio-demographic and clinical characteristics of the two study groups
Laser therapy n= 51 Sham therapy, n= 50 P
Age, median (IQR) 11.9 (7.0–14.7) 11.7 (8.0–14.8) 0.67
Male sex, number (%) 24 (47%) 30 (60%) 0.19
Grade of mucositis, number (%)
Grade 3 30 (59%) 27 (54%) 0.63
Grade 4 21 (41%) 23 (46%)
Type of oncologic disease, number (%)
Acute lymphoblastic leukemia 20 (39%) 21 (42%)
Bonemarrow transplantation 13 (26%) 13 (26%)
Lymphoma 14 (28%) 9 (18%) 0.52
Acutemyeloid leukemia 2 (3.9%) 2 (4.0%)
Other solid tumors 2 (3.9%) 5 (10%)
Total body irradiation, number (%) 5 (9.8%) 8 (16%) 0.06
Neutrophil count, median (IQR) 40.0 (0.0–201.0) 67.5 (0.0–300.0) 0.65
Buccal swab, number (%)
Carried out 21 (44%) 24 (49%)
Positive for candida 1 (1.9%) 1 (2%) 0.61
Positive for HSV 2 (3.9%) 1 (2%)
Presence of mouth or throat symptoms, number (%) 51 (100%) 50 (100%) -
Relevance of mouth or throat symptoms, number (%)
None 0 0
Moderate 5 (9.8%) 5 (10%) 0.61
Severe 20 (39%) 15 (30%)
Very severe 26 (51%) 30 (60%)
Pain score, median (IQR) 8.0 (7.0–8.5) 8.0 (7.0–9.0) 0.47
Presence of pain (pain score> 4), number (%) 48 (94%) 45 (90%) 0.44
Duration of pain in days before enrollment, median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.36
Ongoing treatments, number (%)
Topical mucosal protectants 30 (59%) 34 (68%) 0.34
Topical analgesics 11 (22%) 9 (18%) 0.65
Systemic antimycotics 33 (65%) 38 (76%) 0.21
Systemic antibiotics 39 (77%) 37 (74%) 0.77
Systemic antivirals 31 (61%) 26 (52%) 0.37
Oral analgesics 12 (24%) 11 (22%) 0.86
Parenteral analgesics 33 (65%) 38 (76%) 0.21
Parenteral nutrition 26 (51%) 28 (56%) 0.61
group experienced severe OM versus 28% in the sham group and a
27% increase in patients with OM grade < 3 was observed in the PBM
group. On day 11, only 2.1% of patients in the PBM group had grade 3
mucositis (and no patient had grade 4), whereas 20% of patients in the
sham group still had grade 3 (10%) or 4 (10%)mucositis.
Self-reported pain was significantly reduced in our study: Eliminat-
ing pain is of major interest when treating severeOMand is evenmore
relevant in children for whom pain is usually managed with analgesics
and narcotics that have side effects; of note, Damani and colleagues
reported that codeine and high doses of NSAIDs are among the most
commonly prescribed drugs in cancer pediatrics.20 Although widely
employed, opioid analgesics cannot always adequately palliate severe
OMpain andmay lead to adjunctive problems, such as drymouth, con-
stipation, and impaired conscience. Treatment with PBM has high tol-
erability and compliance, which21 was confirmed in our study. There
were no difficulties in administering PBM to children and young ado-
lescents, nor any side effects or adverse reactions documented in any
patient.Most likely, the acceptance of treatment in young childrenwas
eased by dividing the procedure into two shorter sessions.
The reduction of analgesic consumption was not statistically signif-
icant in our study though the intake of analgesics was not thoroughly
investigated regarding substances, doses, length, ormodality of admin-
istration, as the sample size did not allow for adding statistically sig-
nificant elements to the subject. Khun and colleagues10 evaluated the
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TABLE 2 Study results
Laser therapy
(n= 51)
Sham therapy
(n= 50) P
OMgrade at day+4, number (%)
Grade 4
Grade 3
Grade< 3
7 (14%)
16 (31%)
28 (55%)
12 (24%)
19 (38%)
19 (38%)
0.19
OMgrade at day+7, number (%) (n= 49)
Grade 4
Grade 3
Grade< 3
1 (2.0%)
2 (4.1%)
46 (94%)
8 (16%)
6 (12%)
36 (72%)
0.01
OMgrade at day+11, number (%) (n= 49)
Grade 4
Grade 3
Grade< 3
0
1 (2.1%)
47 (98%)
5 (10%)
5 (10%)
40 (80%)
0.02
Self-reported pain score at day+4, median (IQR) 4 (2–6) 5 (3–7) 0.07
Self-reported pain score at day+7, median (IQR) 1 (0–3) 2.5 (1–5) 0.006
Self-reported pain score at day+11, median (IQR) 0 (0–1) 1 (0–3) 0.01
Analgesic use at day+7, number (%)
Parenteral
Oral
Topical
Combined
No use
15 (31%)
5 (10%)
0
4 (8.2%)
25 (51%)
18 (36%)
8 (16%)
0
5 (10%)
19 (38%)
0.60
Neutrophil count at day+4, median (IQR) 100 (0–800) 104 (0–580) 0.98
Neutrophil count at day+7, median (IQR) 770 (100–1938) 917 (50–2100) 0.79
Neutrophil count at day+11, median (IQR) 1456 (503–4158) 1380 (275–2875) 0.32
Admission due to isolatedOM (n= 48) 6 / 48 (13%) 8 / 50 (16%) 0.62
F IGURE 2 Percentage of patients with OM grade 3–4 in the PBM
group (white columns) and sham group (black columns) on days+1,+4,
+7, and+11
efficacy of laser therapy in a population of children with cancer
including 21 patients, with no stratification between OM grades, with
promising results. The present study investigated the use of PBM in a
similar pediatric population but in a multicenter setting and a broader
sample population. The study was designed to select only severe cases
of OM (grades 3–4) to stress the clinical efficacy of PBM regarding
the restoration of feeding capacity, as grade 2 is generally associated
with a maintained nutritional condition and appropriate food intake.
In this perspective, the reduction of OM grade due to PBMmay result
in concrete clinical and quality of life improvement as the restoration
of feeding capacity is perceived as a strong indicator of patient well-
being, and malnutrition increases the risk of toxicities and infections
but also decreases response and compliance to treatment of patients
with cancer.22
There are some points to note: First, the remarkably high rate of
participation (101 of 102 eligible patients), which might be explained
by the fact that, in spite of thepresenceof highly debilitating andworri-
some symptoms perceived by patients and families, no effective treat-
ments are available yet forOM.Moreover, laser treatment is appealing
due to its non-invasive nature, the absence of expected side effects,
and previous knowledge of the use of modern technology to support
health.
In the samples examined,we registered some dropouts, specifically
twoonday+7andoneonday+11.Onedropout occurreddue todeath
of the patient caused by worsening of the neoplastic condition while
the two others were due to logistical reasons: The patients lived far
from the hospital and decided not to return for follow up on day +11,
and theOMhad already healed.
TheWBCandneutrophil countsweremonitoredover time as previ-
ous studies have demonstrated that blood counts, especially absolute
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neutrophil count, are associated with OM onset and severity.23 In our
study, the efficacy of PBM was not influenced or mediated by alter-
ations in neutrophil counts, as these did not differ in the two groups.
Some limitations are evident in the present study. The majority of
subjects enrolled (data not registered) were hospitalized due to com-
plications secondary to chemotherapy, mainly febrile neutropenia, as
shown by the high rate of administration of parenteral analgesics, par-
enteral nutrition and systemic antibiotics (Table 1 . Specific admittance
due to OM was registered in 12.5 and 16% of patients in the PBM
and sham group, and the difference was not statistically significant
(P < 0.63); in such cases, admittance was generally deemed necessary
at the onset of severe symptoms, which indicated recruitment to the
study. In general, the study was not adequately designed to demon-
strate a possible role for PBM in preventing admittance or shortening
admittance duration.
We have not included the evaluation of oral health status in our
study design. At present, many studies report that the maintenance
of good oral health status reduces the severity of OM but also helps
its healing.24 Other studies have reported that a low decayed, missed,
filled teeth index, plaque index, andbleeding onprobing index are asso-
ciated with less severe OM.25 The MASCC/ISOO guidelines recom-
mend the use of a standardized oral care protocol, including brushing
with a soft toothbrush, flossing, and the use of non-medicated rinses
(e.g., saline or sodium bicarbonate rinses).26
Finally, the possible role of PBM in the prevention of OM has not
been investigated in the present study. Some literature has reported an
effective role of laser therapy in reducing the incidence and severity of
OMwhenperformedbefore the onset of symptoms but nomulticenter
setting has been investigated.27 This aspect should be studied in the
future.
At present, our study confirms that PBM is safe, feasible, and effec-
tive and should be introduced as the standard therapy for pediatric
patients affected byOM.
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